Safe Harbor Statement

Transcription

1

2 Safe Harbor Statement This presentation may contain forward-looking statements as defined in the Private Securities Litigation Reform Act of These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from the Company s expectations and projections. Risks and uncertainties include general industry conditions and competition; economic conditions, such as interest rate and currency exchange rate fluctuations; technological advances and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approvals; domestic and foreign health care reforms and governmental laws and regulations; and trends toward health care cost containment. A further list and description of these risks, uncertainties and other factors can be found in Exhibit 99 to the Company s Annual Report on Form 10-K for the fiscal year ended January 3, Copies of this Form 10-K, as well as subsequent filings, are available online at or on request from the Company. The Company does not undertake to update any forward-looking statements as a result of new information or future events or developments.

3 Gary Pruden Company Group Chairman Worldwide Franchise Chairman ETHICON

4 Restoration of Body and of Life 2

5 A Legacy of Quality, Innovation & Performance 1887 incorporated

6 Transforming Our Portfolio of Businesses PROFESSIONAL WOUND CARE

7 ETHICON Franchise SALES YE 2009 GROWTH 2009 CAGR WW MARKET POSITION 2009* $4.1B 10.7% 6.6% #1 Growth Strategies Grow our core businesses faster than the market Emerging markets Innovation Globalize new growth platforms Penetration of O.U.S. markets Portfolio expansion Capitalize on convergence * Internal Estimates Note: All growth figures operational 5

8 Grow Our Core Businesses Faster Than the Market Wound Closure, Hernia Repair, Women s Health 6

9 Core Platforms: Performance Overview PLATFORM SALES GROWTH 2009 WW MARKET POSITION 2009* WW MARKET CAGR* TOTAL WW MARKET REVENUE 2014* Wound closure 3.4% #1 4.0% $4.3B Hernia repair 20.0% #2 8.6% $1.5B Women s health 4.3% #2 8.6% $2.4B Wound closure: Growth in suture and beyond Address unmet needs; build Topical Skin Adhesive (TSA) platform; accelerate growth in emerging markets Hernia repair: Consistent year-over-year, +20% WW Growth* ( 06-09) Leadership in partially absorbable, large pore mesh market; driving growth through portfolio innovation Women s health: Largest portfolio of women s health devices on the market today Low market penetration; driving growth through new product introduction * Internal Estimates Note: All figures operational 7

10 Growth through Geographic Market Expansion WW Suture Sales * Emerging Developed Top 10 Markets RANK 2014 SALES* 1 U.S. 25% 32% 2 Japan 3 China 75% 68% 4 Germany 5 India 6 Italy Significant market growth across all emerging markets Market appropriate products (e.g., SYNSYL Suture) provide access to new customers; balance needs of premium and S2 markets 7 UK 8 France 9 Brazil 10 Russia * ETHICON Internal Estimates 8

11 Growth through Innovation: Introducing ETHICON SECURESTRAP ETHICON s first entry into mechanical fixation for use in both laparoscopic and open hernia repair (FDA Clearance: April 2010) Addresses unmet market needs including: Holding strength at various angle of firing Secure fixation via strap (vs. tack) design Low profile strap design to minimize risk of tissue attachment U.S. launch in Q3 2010, estimated $200MM worldwide market in 2010 for hernia fixation Fiber capture in PROCEED mesh 6.7 mm 4.9 mm grip 3.5 mm 9

12 Growth through Innovation: Introducing ETHICON PHYSIOMESH Flexible Composite Mesh Leverages trusted ETHICON polymer technology Thin-filament, large pore design Stretches to closely match the abdominal wall Excellent tissue integration Offers surgeons excellent intra-operative handling, ease-of-deployment, ease-of-positioning Opportunity for incremental penetration of ventral hernia market Total tissue separating mesh market = $195MM* in U.S. * IMS Market Data; MAT March 2009 February

13 Globalize New Growth Platforms ENT, Aesthetics, Biosurgicals 11

14 ENT (Ear, Nose & Throat) SALES GROWTH 2009 WW MARKET POSITION 2009* WW MARKET CAGR* TOTAL WW MARKET REVENUE 2014* N/A #1 9.4% $2.0B ENT: Large, underserved market opportunity Chronic rhinosinusitis million U.S. patients Obstructive sleep apnea million U.S. patients Hearing impairment and loss million U.S. patients Acclarent acquired January 2010 opportunity to expand beyond U.S. market Balloon Sinuplasty represents paradigm shift in treating symptoms of sinusitis Robust pipeline: Airway disorders, Myringotomy (ear tube) procedure, visualization * Internal Estimates Note: All figures operational 12

15 Acclarent Balloon Sinuplasty Device Demonstration 13

16 Aesthetics SALES GROWTH 2009 WW MARKET POSITION 2009** WW MARKET CAGR*** TOTAL WW MARKET REVENUE 2014*** N/A #1 9.0% $4.1B January 2009 acquired Mentor: U.S. market leader in breast aesthetics 2009: U.S. share growth of 2 pts.*, offset procedural declines due to economy Breast implant market growth minus 20% Q1 2009; return to growth Q Capitalizing on ETHICON global footprint to drive O.U.S. reach and growth Expanding beyond breast aesthetics to fuel new growth in breast reconstruction, surgical facial aesthetics and body aesthetics * Guidepoint Tracker ** Internal Estimates Breast implant market *** Internal Estimates Aesthetics market Note: All figures operational 14

17 Growth through New Surgical Aesthetic Procedures NUVANCE Facial Rejuvenation System (minimally invasive face lift) received CE Mark approval in 2009 Minimal dissection required Can be performed as outpatient procedure Built on ETHICON mesh technology Patient clinical trials underway in EMEA Designed to fill significant unmet need Less invasive surgical options 15

18 Biosurgicals SALES GROWTH 2009* WW MARKET POSITION 2009** WW MARKET CAGR** TOTAL WW MARKET REVENUE 2014** 9.6% #1 10.3% $2.9B Acquired Omrix December 30, 2008 Capitalizing on global footprint to drive O.U.S. growth: EVICEL Fibrin Sealant (Human) now available in over 14 countries Significant growth opportunities to expand beyond hemostasis to seal leaks, join structures and enhance healing * Pro-Forma (assumes FY Omrix sales in 2008) ** Internal Estimates Note: All figures operational 16

19 The Fibrin Pad Product Candidate Anticipated BLA filing: 4Q10 Product combines two biomaterials and two biologics Capitalizes upon JNJ convergence (ETHICON/Centocor) Described during November 2009 Meeting* for Project Hercules by: Dr. Mauro Longoni Hospital Di Sesto, Milan, Italy Dr. Romans Lacis Paula Stradins University Hospital Cardiac Surgery Center Chairman, Riga, Latvia * Physicians may have received compensation for their participation in ETHICON Ad Board meetings 17

20 ETHICON Pipeline Highlights Approved*/Cleared* PROCEED Ventral Patch (EU) PDS Plus Antibacterial (polydioxanone) Suture (EU) PDS Flexible Plates (U.S. and EU) SURGIFLO with Integrated Thrombin Kit NUVANCE Facial Rejuvenation System (EU) PREVELLE Lift Dermal Filler (EU) ETHICON SECURESTRAP 5mm Strap Fixation Device ETHICON PHYSIOMESH Flexible Composite Mesh Mentor Sensitive Anatomical Gel (EU) GYNECARE MORCELLEX Re-Launch GYNECARE PROSIMA Pelvic Floor Repair System GYNECARE TVT EXACT Continence System ETHICON OMNEX Surgical Sealant Submitted* DERMABOND Topical Skin Adhesive New Formulation Planned Submissions* Fibrin Pad (EU) VICRYL RAPIDE Plus Suture SURGIFLO with Integrated Thrombin GYNECARE SUI Sling Next Generation Kit (EU) PurTox Highly Purified Botulinum Neurotoxin 2010 Planned Submissions* EVERPOINT Cardiovascular Needles Fibrin Pad (BLA) GYNECARE TVT ABBREVO Continence System GYNECARE V-Support Treatment Project Acclarent CYCLOPS Multi-Angle Endoscope Acclarent RELIEVA LUMA II Catheter Planned Submissions* ETHICON Next Generation Wound Closure Project Mentor Becker Round Adjustable Gel GYNECARE Next Generation Pelvic Floor Repair Project * Filings/approvals assumed to be in U.S. unless otherwise noted Selected highlights as of 6/3/10. This information is accurate as of the date hereof to the best of the Company s knowledge. Johnson & Johnson/ETHICON assumes no obligation to update this information 18

21 In Summary Growing our leading market positions across core platforms Positioned for accelerated growth New growth platforms Penetration of O.U.S. and strategic emerging markets Evolving our technology From biomaterials to biologically active biomaterials Differentiated, strong pipeline across all platforms Commitment and track record of strong performance 19

22